NCT06908018View on ClinicalTrials.gov

Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2028

Conditions
Safety IssuesDengueViremiaImmune-related Adverse Event
Interventions
BIOLOGICAL

rDEN2Δ30-7169

rDEN2Δ30-7169 is a recombinat virus that could induce viremia and immunological responses with out serious adverse effect. The virus will be challenged after participants screening and consent for hospitalization. After virus challenge, the virological, immunological and clinical manifestation will be recorded and analyzed for the result from day 0-60 post-virus challenge.

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Johns Hopkins University

OTHER

lead

Mahidol University

OTHER